drugset

drugset / Trial / NCT02182141

An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma

NCT02182141 ↗

Phase 1 Completed 17 enrolled Boehringer Ingelheim

NaSingle-groupOpen-labelTreatment

Summary

Maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of BIBF 1120, pharmacodynamics

Timeline

Start: 2003-04
Primary completion: 2005-03
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nintedanib	Small molecule	—	Oral

Indications